DLBCL: Clinical Trials

2 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 2

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma
Phase 1 / Phase 2CompletedCyteir Therapeutics, Inc.1692019-10-092024-12-24
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
IONIS-STAT3Rx - Advanced Cancers, DLBCL
Phase 1 / Phase 2CompletedIonis Pharmaceuticals, Inc.642012-02-272018-06-25

Narrower conditions

Breast Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Sarcoma (1)  ·  Small Cell Lung Carcinoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Adnexal Diseases (1)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Squamous Cell (1)  ·  Cardiovascular Diseases (1)  ·  Digestive System Diseases (1)

Interventions

Bendamustine Hydrochloride (1)  ·  Capecitabine (1)  ·  Gemcitabine (1)  ·  Rituximab (1)

Sponsors

Cyteir Therapeutics, Inc. (1)  ·  Ionis Pharmaceuticals, Inc. (1)

Countries

United States (2)

Top investigators

Markus Renschler, MD (1)  ·  Steve Hughes, MD (1)

Results publications

PMID 30446007